A new article published in the Cell Reports describes how a new drug is able to reduce the symptoms and activate the dormant neurons characteristic of Rett Syndrome in preclinical models. The study, led by Dr. Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL), ICREA Researcher and […]
A new drug shows preclinical efficacy in Rett syndrome Read More »
The Bellvitge Biomedical Research Institute (IDIBELL) has recently signed a collaboration agreement with the Institute of Legal Medicine and Forensic Sciences of Catalonia (IMLCFC). The main objective of this agreement is to establish a collaboration between both institutions to jointly develop programs and activities linked to biomedical research, as well as to achieve significant improvements
New collaboration agreement between IDIBELL and IMLCFC Read More »
Researchers of the proCURE program of the Catalan Institute of Oncology, Oncobell-IDIBELL, have recently published a scientific paper in which they describe the genetic mechanisms by which a breast tumor associated to a mutated BRCA1 gene becomes resistant to chemotherapy. Breast cancers that appear in women with BRCA1 mutations usually present a poor prognosis
How does BRCA1 breast cancer become resistant to chemotherapy? Read More »
Collaboration between basic and clinical research groups at Bellvitge leads to the first therapy for this disease The work of researchers Francesc Viñals and Mariona Graupera at the Bellvitge Biomedical Research Institute (IDIBELL, Oncobell program) – Catalan Institute of Oncology (ICO, ProCURE program) – University of Barcelona, together with Dr. Antoni Riera-Mestre (IDIBELL, Bellvitge University
Scientists identify a potential treatment for Hereditary Hemorrhagic Telangiectasia Read More »
The development of the EPICUP epigenomic tool, capable of improving the diagnosis of metastases of unknown origin, has been awarded the Prize for Scientific Innovation in its Clinical Research modality by the Pfizer Foundation, which was given to the first author of the study, Dr. Sebastian Morán, at an event held at the Hospital la
The EPICUP Project receives a Pfizer Foundation Innovation award Read More »
IDIBELL celebrates the first edition of its Accelerator Meeting Point The Bellvitge Biomedical Research Institute (IDIBELL) held yesterday April 16th the first edition of its Accelerator Meeting Point, a meeting where CataloniaBio -association of biomedicine and health companies in Catalonia-, Biocat -institution responsible for the promotion of the life sciences and health sector in Catalonia-
Bringing research closer to the industry Read More »
On April 13th and 14th, IDIBELL held its annual scientific retreat at the Bellvitge Cultural Center. During two days that were attended by more than 150 people between group leaders, principal investigators and external collaborators, IDIBELL presented its research programs and gave the firing shot to the preparation of the new Strategic Plan 2018-2021. The
IDIBELL redefines itself in its annual Retreat Read More »
The group of Dr. Conxi Lázaro, principal investigator of the Hereditary cancer research group of the Oncobell program (IDIBELL) and head of the Molecular Diagnostic Unit of the Hereditary Cancer Program (ICO), has received one of the Neurofibromatosis Research Grants of the Neurofibromatosis Proyecto Foundation in its Call 2018. The two-year grant, worth € 40,000,
€ 40,000 to move forward developing therapies against MPNST Read More »
Researchers led by Dr. Virginia Nunes (IDIBELL, UB, CiBERER U730) and Dr. Manuel Palacín (IRBB, UB, CIBERER U731) have demonstrated, for the first time, in vivocooperation of two basolateral transporters of neutral amino acids and their involvement in the renal reabsorption of these amino acids. The work, published in the Journal of the American Society of Nephrology (JASN),
The Oncobell sarcoma research group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Òscar Martínez-Tirado, has identified a potential new therapeutic target for Ewing sarcoma, the second most frequent bone cancer in children and adolescents, and a tumor known by its aggressiveness and tendency to metastasize. The research, published in International Journal of Cancer, has
A potential new therapeutic target for Ewing sarcoma Read More »
